Lympathic Mapping with SPECT-CT guided Radiotherapy for Oropharyngeal Cancer
This trialis testing if using imaging to guide radiation therapy to one side of the neck can reduce risk of cancer returning or spreading.
- Oropharyngeal Cancer
1 Primary · 13 Secondary · Reporting Duration: 8 years
2 Treatment Groups
Bilateral Neck Radiotherapy
1 of 2
Lympathic Mapping with SPECT-CT guided Radiotherapy
1 of 2
510 Total Participants · 2 Treatment Groups
Primary Treatment: Lympathic Mapping with SPECT-CT guided Radiotherapy · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 13 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has the FDA issued authorization for Lympathic Mapping with SPECT-CT guided Radiotherapy?
"There is prior clinical evidence that supports the saftey of Lympathic Mapping with SPECT-CT guided Radiotherapy, thus it was rated a 3 on our scale." - Anonymous Online Contributor
What is the enrollment size of this experiment?
"Affirmative. Clinicaltrials.gov has information that this research is currently recruiting, having been posted on September 29th 2022 and updated as recently as February 3rd 2023. The medical experiment seeks to enrol 510 participants from a single site." - Anonymous Online Contributor
Is enrollment into this experiment currently open to participants?
"Affirmative. As denoted on clinicaltrials.gov, this research was first made public in September 2022 and recently updated in February 2023. The study is enrolling 510 volunteers at a single site." - Anonymous Online Contributor